Literature DB >> 11840385

Treatment of systemic lupus erythematosus by immunoadsorption in a patient suffering from tuberculosis.

Sabine Schmaldienst1, Martin Jansen, Ursula Hollenstein, Winfried Graninger, Heinz Regele, Walter Hermann Hörl, Kurt Derfler.   

Abstract

We report on a 40-year-old man, admitted with fever and weight loss, in whom systemic lupus erythematosus (lupus nephritis World Health Organization type IV) and concomitant acute lung tuberculosis were diagnosed. Conventional treatment of diffuse proliferative nephritis with cytotoxic drugs was thought to be too dangerous in the presence of active tuberculosis. A combination of immunoadsorption and steroids was instituted for the treatment of systemic lupus erythematosus. Antibodies against double-stranded DNA decreased, and proteinuria decreased from 10 g/24 hours to less than 1 g/24 hours. Tuberculosis was treated initially with quadruple-drug therapy, then a triple-drug protocol. Primarily enlarged lymph nodes decreased to normal size after 3 months. The combined treatment modality of steroids and immunoadsorption was effective and safe, even in this patient with active tuberculosis. Copyright 2002 by the National Kidney Foundation, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11840385     DOI: 10.1053/ajkd.2002.30564

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  6 in total

1.  Immunoadsorption of alloantibodies onto erythroid membrane antigens encapsulated into polymeric microparticles.

Authors:  Valérie Hoffart; Philippe Maincent; Alf Lamprecht; Véronique Latger-Cannard; Véronique Regnault; Christian Merle; Valérie Jouan-Hureaux; Thomas Lecompte; Claude Vigneron; Nathalie Ubrich
Journal:  Pharm Res       Date:  2007-06-14       Impact factor: 4.200

2.  Rapid reduction of antibodies and improvement of disease activity by immunoadsorption in Chinese patients with severe systemic lupus erythematosus.

Authors:  Jinxian Huang; Guoxiang Song; Zhihua Yin; Weizhen He; Lijun Zhang; Weihong Kong; Zhizhong Ye
Journal:  Clin Rheumatol       Date:  2016-08-03       Impact factor: 2.980

3.  IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study.

Authors:  G H Stummvoll; M Aringer; J S Smolen; S Schmaldienst; E Jiménez-Boj; W H Hörl; W B Graninger; K Derfler
Journal:  Ann Rheum Dis       Date:  2005-01-07       Impact factor: 19.103

4.  [Selective immunoadsorption in neurologic complications of systemic lupus erythematosus].

Authors:  S Harscher; S Rummler; P Oelzner; H-J Mentzel; M Brodhun; O W Witte; C Terborg; S Isenmann
Journal:  Nervenarzt       Date:  2007-04       Impact factor: 1.214

5.  iTRAQ-Based Comparative Proteomics Analysis of Urolithiasis Rats Induced by Ethylene Glycol.

Authors:  Yanan Cao; Bin Duan; Xiaowei Gao; E Wang; Zhitao Dong
Journal:  Biomed Res Int       Date:  2020-05-15       Impact factor: 3.411

6.  Long-term outcome of anti-glomerular basement membrane antibody disease treated with immunoadsorption.

Authors:  Peter Biesenbach; Renate Kain; Kurt Derfler; Thomas Perkmann; Afschin Soleiman; Alexandra Benharkou; Wilfred Druml; Andrew Rees; Marcus D Säemann
Journal:  PLoS One       Date:  2014-07-31       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.